Emles Real Estate Credit ETF REC
Set alert
As of Jun 12, 9:41 AM ET
- Open
- 20.06
- Prev close
- 20.06
- Mkt cap
- 4.06M
- Vol
- 48
- Avg vol
- 48
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 20.06
- High
- 20.06
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 29.45
- 200-d avg
- 29.45
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 29.45
- 200-day average
- 29.45
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Emles Real Estate Credit ETF
Emles Trust - Emles Real Estate Credit ETF is an exchange traded fund launched and managed by Emles Advisors LLC. The fund invests in the fixed income markets of the United States. The fund invests in debt securities of companies operating in the real estate sector. It primarily invests in investment-grade corporate bonds that are rated B3 by Moody's Investors Service, Inc. or higher or the equivalent rating on either S&P Global Ratings or Fitch Ratings, Inc. It includes fixed rate bonds, zero-coupon bonds, step-up bonds, fixed-to-float bonds (provided they are currently fixed) and non-convertible bonds, and shall exclude convertible bonds and floating rate bonds. The fund invests in securities with maturities of 36 months or more at the time of issuance and 12 months at the time of rebalancing, that have $100 million or more current face value. Emles Trust - Emles Real Estate Credit ETF is domiciled in the United States.
- Country
- United States
News
- Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
- New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
Your note
Sign in to keep a note on REC — it syncs with the Stock Master app.